Galera to Present at Jefferies Healthcare Conference
Galera Therapeutics (Nasdaq: GRTX) announced that Dr. Mel Sorensen, CEO, will present at the 2022 Jefferies Healthcare Conference on June 9 at 2:00 p.m. E.T. The presentation will highlight the company's innovative therapies aimed at transforming cancer radiotherapy. Investors can access a live webcast on Galera's investor page, and an archived version will be available for 30 days post-event. Galera's leading products include avasopasem manganese and rucosopasem manganese, focused on mitigating radiotherapy-induced toxicities and enhancing treatment efficacy in specific cancers.
- None.
- None.
MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. E.T.
A live webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the Events & Presentations section of the Investors page of Galera’s website for 30 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.
Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com
William Windham
Solebury Trout
646-378-2946
wwindham@soleburytrout.com
Media Contact:
Zara Lockshin
Solebury Trout
646-378-2960
zlockshin@soleburytrout.com
FAQ
When is Galera Therapeutics presenting at the Jefferies Healthcare Conference?
How can I watch the Galera Therapeutics presentation?
What is the focus of Galera Therapeutics' product development?
What are the main product candidates of Galera Therapeutics?
What therapeutic areas do Galera's candidates target?
